The financing proceeds will be used to accelerate the company's innovative platform TangenDx to the clinic for two infectious disease tests.
TangenDx is a novel isothermal nucleic acid detection platform that enables molecular diagnostic technology to move out of traditional laboratories by providing low cost, portable, and rapid diagnostic capabilities with unparalleled sensitivity for a variety of applications.
Tangen Biosciences is led by CEO, Richard C. Birkmeyer, PhD, an experienced executive who joined the company in November 2018.
Birkmeyer previously led two start-up diagnostic companies from infancy to successful exits. Tangen also expanded its management team to include Keith Kardos, PhD, acting VP of Clinical Affairs, and Anne Cavanaugh, director of Finance.
Keith has over 25 years of experience managing R and D programs. Keith was formerly employed as the VP of R and D for OraSure Technologies, Inc. and VP of Clinical Affairs for CD Diagnostics.
Anne is a successful entrepreneur who co-founded Strategic Diagnostics Inc.
Strategic Diagnostics became a public company and grew to a USD 200m market capitalization with over 200 employees.
In anticipation of a 2020 product launch, Tangen Biosciences will be relocating its office to a new 16,200 square foot facility located in Branford, CT in August 2019.
Tangen Biosciences was founded in 2013 and is located in Branford, Connecticut.
The company developed the TangenDx platform for fast and accurate detection of targeted DNAs and RNAs directly from specimens by using rapid isothermal nucleic acid detection.
Use of Tangen's system, which does not require laboratory facilities and delivers faster, simpler, more sensitive detection; at lower cost than existing commercial technologies. The TangenDx platform is on track for infectious disease clinical trials.
Connecticut Innovations is the leading source of financing and ongoing support for Connecticut's innovative, growing companies.
To maximise growth potential, CI provides venture capital and strategic support for early-stage technology companies; financial support for innovation and collaboration; and connections to its well-established network of partners and professionals.
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer
Oxford Biomedica to acquire ABL Europe
RedHill Biopharma granted five years' market exclusivity for Talicia by US FDA
SK bioscience signs development licensing agreement with Hilleman Laboratories
Poolbeg Pharma expands patent portfolio with Immunomodulator II approval in Japan
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation